Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptors (TCRs) recognizing Aspergillus fumigatus peptide–MHC class II complexes are specialized immune receptors that play a pivotal role in the recognition and clearance of the opportunistic fungal pathogen Aspergillus fumigatus (Bacher et al., 2014, PubMed: 25255142). These receptors, primarily found on CD4+ T cells, specifically bind to immunodominant fungal antigens such as Crf1, Gel1, and Shm1 when they are presented by Major Histocompatibility Complex (MHC) class II molecules on the surface of antigen-presenting cells (Tramsen et al., 2009, PubMed: 19124355). This binding event initiates a signaling cascade that leads to T-cell activation and the production of pro-inflammatory cytokines, including interferon-gamma (IFN-γ), which are critical for activating phagocytes to eliminate fungal hyphae (Stuehler et al., 2015, PubMed: 25533486). In the clinical landscape, these TCRs are being investigated as therapeutic targets for adoptive T-cell therapy (ACT) to restore fungal-specific immunity in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation (Jolink et al., 2013, PubMed: 23836561). By utilizing T cells with high-affinity TCRs for Aspergillus, clinicians aim to provide a targeted cellular treatment for invasive aspergillosis, which remains a leading cause of mortality in transplant recipients.
Recognition of Aspergillus-derived peptides presented by MHC class II molecules, leading to CD4+ T-cell activation, secretion of Th1 cytokines (e.g., IFN-gamma), and enhancement of antifungal effector functions in phagocytes.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Aspergillus fumigatus peptide–MHC class II complex (Af-specific TCR).